Cantor Fitzgerald Reiterates Overweight Rating on Celldex Therapeutics, Inc. (CLDX)
Rating Change Cantor Fitzgerald analysts reiterated a Overweight rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) on July 22, 2026. Market Context Celldex Therapeutics, Inc.
Read more
